
CLAIMS

WHAT IS CLAIMED IS:

1. ~~A method of treating plexiform neurofibroma, comprising the steps of:~~

~~providing~~Use of at least one ~~a~~therapeutically effective dose of a compound according to Formula **1**:



(1)

in the preparation of a medicament for the treatment of plexiform neurofibroma, wherein,

R_1 is 4-pyrazinyl; 1-methyl-1H-pyrrolyl; amino- or amino-lower alkyl-substituted phenyl, wherein the amino group in each case is free, alkylated or acylated; 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom; or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen;

R_2 and R_3 are each independently of the other hydrogen or lower alkyl;

one or two of the radicals R_4, R_5, R_6, R_7 and R_8 are each nitro, fluoro-substituted lower alkoxy or a radical of formula II

$$-N(R_9)-C(=X)-(Y)_n-R_{10} \qquad \text{(II)};$$

wherein,

R_9 is hydrogen or lower alkyl,

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydroximino,

Y is oxygen or the group NH,

n is 0 or 1 and

R_{10} is an aliphatic radical having at least 5 carbon atoms, or an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or heterocyclic-aliphatic radical,

and the remaining radicals R_4, R_5, R_6, R_7 and R_8 are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified or esterifed hydroxy, free, alkylated or acylated amino or free or esterified carboxy,

or of a salt of such a compound having at least one salt-forming group, wherein the therapeutically effective dose of the compound is on the order of between about 200 mg to about 500 mg and the dose of the compound is for administration to a patient at least once per day.

2. The ~~method~~use according to claim 1, wherein the compound is a pharmaceutically acceptable salt of Formula **1**.

3. The ~~method~~use according to claim 2, wherein the pharmaceutically acceptable salt of Formula **1** is a mesylate salt.

~~4. The method according to claim 1, further including the step of;~~

~~diagnosing a patent with plexiform neurofibroma or a similar condition.~~

~~5. The method according to claim 1, further including the step of;~~

~~identifying a patent at risk for developing plexiform neurofibroma or a similar condition.~~


~~6. The method according to claim 1, wherein the therapeutically effective dose of the compound according to Formula **1**, is on the order of between about 200 mg to about 500 mg and the dose of the compound is administered to at patient at least once per day.~~

~~7~~4. The ~~method~~use according to claim 1, wherein the therapeutically effective dose of the compound according to Formula **1**, is on the order of between about 350 mg to about 450 mg and the dose of the compound is ~~administered~~for administration to a~~t~~ patient at least once per day.

~~8~~5. The ~~method~~use according to claim 1, wherein the therapeutically effective dose of the compound according to Formula **1**, is about 400 mg and the dose of the compound is ~~administered~~for administration to a patient twice per day.

~~9~~6. ~~A method of treating plexiform neurofibroma, comprising the steps of:~~

~~providing~~Use of at least one ~~-~~therapeutically effective dose of a compound according to Formula **2**:



(2)

in the preparation of a medicament for the treatment of plexiform neurofibroma, wherein the therapeutically effective dose of the compound is on the order of between about 200 mg to about 500 mg and the dose of the compound is for administration to a patient at least once per day.

~~10~~7. The ~~method~~use according to claim ~~9~~6, wherein the compound is a pharmaceutically acceptable salt of Formula **2**.

~~11. The method according to claim 9, further including the step of;~~

~~diagnosing a patent with plexiform neurofibroma or a similar condition.~~

~~12. The method according to claim 9, further including the step of;~~

~~identifying a patent at risk for developing plexiform neurofibroma or a similar condition.~~


~~13. The method according to claim 9, wherein the therapeutically effective dose of the compound according to Formula **2**, is on the order of between about 200 mg to about 500 mg and the dose of the compound is administered to at patient at least once per day.~~

~~14~~8. The ~~method~~use according to claim ~~9~~6, wherein the therapeutically effective dose of the compound according to Formula **2**, is on the order of between about 350 mg to about 450 mg and the dose of the compound is ~~administered~~for administration to a~~t~~ patient at least once per day.

~~15~~9. The ~~method~~use according to claim ~~9~~6, wherein the therapeutically effective dose of the compound according to Formula **2**, is about 400 mg and the dose of the compound is ~~administered~~for administration to a patient twice per day.

~~16~~10. ~~A method of treating plexiform neurofibroma, comprising the steps of:~~

~~providing~~Use of at least one ~~-~~therapeutically effective dose of a compound according to Formula **3**:



(3)

in the preparation of a medicament for the treatment of plexiform neurofibroma, wherein the therapeutically effective dose of the compound is on the order of between about 200 mg to about 500 mg and the dose of the compound is for administration to a patient at least once per day.

~~17. The method according to claim 16, further including the step of;~~

~~diagnosing a patent with plexiform neurofibroma or a similar condition.~~

~~18. The method according to claim 16, further including the step of;~~

~~identifying a patent at risk for developing plexiform neurofibroma or a similar condition.~~

~~19. The method according to claim 16, wherein the therapeutically effective dose of the compound according to Formula **3**, is on the order of between about 200 mg to about 500 mg and the dose of the compound is administered to at patient at least once per day.~~

~~20~~11. The ~~method~~use according to claim ~~16~~10, wherein the therapeutically effective dose of the compound according to Formula **3**, is on the order of between about 350 mg to about 450 mg and the dose of the compound is ~~administered~~for administration to a~~t~~ patient at least once per day.

~~21~~12. The ~~method~~use according to claim ~~16~~10, wherein the therapeutically effective dose of the compound according to Formula **3**, is about 400 mg and the dose of the compound is ~~administered~~for administration to a patient twice per day.